Eqis Capital Management Inc. reduced its stake in shares of AMETEK, Inc. (NYSE:AME) by 15.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,008 shares of the technology company’s stock after selling 4,070 shares during the quarter. Eqis Capital Management Inc.’s holdings in AMETEK were worth $1,490,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in the stock. IFP Advisors Inc raised its position in AMETEK by 76.4% in the fourth quarter. IFP Advisors Inc now owns 441 shares of the technology company’s stock valued at $29,000 after purchasing an additional 191 shares during the period. Cerebellum GP LLC raised its holdings in shares of AMETEK by 86.7% in the 4th quarter. Cerebellum GP LLC now owns 1,064 shares of the technology company’s stock valued at $72,000 after buying an additional 494 shares during the period. ELM Advisors LLC purchased a new stake in shares of AMETEK in the 3rd quarter valued at $142,000. Advisors Asset Management Inc. purchased a new stake in shares of AMETEK in the 2nd quarter valued at $168,000. Finally, Fuller & Thaler Asset Management Inc. raised its holdings in shares of AMETEK by 114.3% in the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 2,250 shares of the technology company’s stock valued at $178,000 after buying an additional 1,200 shares during the period. Institutional investors own 84.33% of the company’s stock.
AME has been the topic of several research analyst reports. Morgan Stanley upgraded AMETEK from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $81.00 to $85.00 in a report on Tuesday, December 18th. Wolfe Research upgraded AMETEK from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 8th. Stephens restated a “buy” rating and set a $79.00 price target on shares of AMETEK in a report on Sunday, January 6th. BMO Capital Markets cut their price target on AMETEK from $93.00 to $91.00 and set an “outperform” rating on the stock in a report on Friday, November 2nd. Finally, Royal Bank of Canada restated a “buy” rating and set a $82.00 price target on shares of AMETEK in a report on Wednesday, December 19th. Twelve analysts have rated the stock with a buy rating, AMETEK currently has a consensus rating of “Buy” and a consensus price target of $86.10.
Shares of NYSE AME opened at $75.76 on Monday. The stock has a market capitalization of $17.59 billion, a P/E ratio of 23.03, a PEG ratio of 2.03 and a beta of 1.20. The company has a quick ratio of 1.42, a current ratio of 1.46 and a debt-to-equity ratio of 0.54. AMETEK, Inc. has a 52-week low of $63.14 and a 52-week high of $81.92.
AMETEK (NYSE:AME) last posted its quarterly earnings data on Tuesday, February 5th. The technology company reported $0.86 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.84 by $0.02. The firm had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.26 billion. AMETEK had a return on equity of 17.72% and a net margin of 16.05%. The firm’s revenue was up 11.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.70 EPS. As a group, research analysts forecast that AMETEK, Inc. will post 3.92 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Eqis Capital Management Inc. Has $1.49 Million Stake in AMETEK, Inc. (NYSE:AME)” was originally reported by Fairfield Current and is owned by of Fairfield Current. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.fairfieldcurrent.com/news/2019/02/11/eqis-capital-management-inc-has-1-49-million-stake-in-ametek-inc-ame.html.
AMETEK Company Profile
AMETEK, Inc manufactures and sells electronic instruments and electromechanical devices worldwide. Its Electronic Instruments Group segment offers advanced instruments for the process, power and industrial, and aerospace markets; process and analytical instruments for the oil, gas, petrochemical, pharmaceutical, semiconductor, automation, and food and beverage markets; and instruments for the laboratory equipment, ultraprecision manufacturing, medical, and test and measurement markets.
Further Reading: What does the Dow Jones Industrial Average (DJIA) measure?
Receive News & Ratings for AMETEK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMETEK and related companies with MarketBeat.com's FREE daily email newsletter.